Post-remission Therapy with Repeated Courses of High Dose Cytarabine, Idarubicin and Limited Autologous Stem Cell Support Achieves a Very Good Long-Term Outcome in ELN Favorable and Intermediate-Risk AML
| Image |  |
|---|---|
| Description | scientific article published on 19 September 2020 |
| Author/s |
author: Erika Borlenghi Giuseppe Rossi |
| Publication date | September 19, 2020 |
| Language | |
| Country of origin | |
| Wikipedia link | |
| Copyright status | |
| Missing/wrong data? | Edit Wikidata item |